Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Espey Mfg. & Electronics Corp. reported third quarter fiscal 2026 results showing higher net income and earnings per share compared to the prior year quarter despite a slight decline in nine-month sales and new orders. The company highlights strong backlog and a focus on margin expansion through favorable product mix, operational leverage, and cost…
Neumora Therapeutics, a clinical-stage biopharmaceutical company focusing on novel neuroscience drug development, announced it will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026. The event will be webcast live and archived for up to 30 days.
Nyxoah SA announced its Q1 2026 financial results highlighted by a robust 25% sequential growth in U.S. net revenue owing to the strong commercial launch of its Genio hypoglossal neurostimulation system for obstructive sleep apnea (OSA). The company continues to gain surgeon trainees and account activations, alongside achieving 100% prior authoriza…
Red Cat Holdings, a U.S.-based defense and national security drone and robotic solutions provider, has announced a proposed underwritten public offering of $200 million in common stock with an option for underwriters to purchase an additional $30 million. The proceeds will be used for general corporate purposes including acquisitions, R&D, capital …
Biomea Fusion, a clinical-stage company specializing in diabetes and obesity treatments, announced its management's planned participation in upcoming investor conferences in New York. The company will present updates on its oral small molecule therapies targeting metabolic disorders, including icovamenib and BMF-650. Webcasts of the sessions will b…
Pharvaris reports Q1 2026 financial results, confirms on-track NDA submission for deucrictibant IR in HAE treatment, and anticipates pivotal Phase 3 CHAPTER-3 study topline data by Q3 2026. Enrollment continues in pivotal studies targeting hereditary and acquired angioedema. Successful $132 million offering enhances cash runway into 2028, supportin…
Digital Realty, a leading global data center platform company, declared quarterly cash dividends for its common stock and four series of cumulative redeemable preferred stock for Q2 2026. Dividends will be paid on June 30, 2026, to shareholders of record on June 15, 2026.
Rezolute, Inc. announced Q3 fiscal 2026 financial results and provided a business update, highlighting significant clinical benefits in their Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism (HI). The data demonstrated clinically relevant and nominally statistically significant reductions in hypoglycemia and improvements in glycemi…
Elevra Lithium Limited has purchased and terminated the discounted life-of-mine spodumene concentrate offtake agreement previously held by Waratah Capital Advisors for the Moblan Lithium Project, increasing its control to 100% of the project's lithium concentrate output. The transaction was equity-based, preserving cash, and is expected to strength…
Atea Pharmaceuticals reported Q1 2026 financial results and provided updates on its antiviral drug development programs. The company is progressing two pivotal Phase 3 trials for its oral HCV regimen bemnifosbuvir/ruzasvir with topline results expected mid and late 2026, respectively. Encouraging preclinical data support the advancement of AT-587, …
Robinhood Markets, Inc. announced that its Chief Brokerage Officer will present at the J.P. Morgan Global Technology, Media and Communications Conference on May 19, 2026. The presentation will be webcast live and available for replay, providing insights into the company's business and strategy. This participation offers transparency and engagement …
Varonis Systems, Inc., a leader in data and AI security, will participate in several upcoming investor conferences including J.P. Morgan, TD Cowen, and William Blair in the US. Presentations will cover the company's AI security solutions and will be webcast live.
Black Rock Coffee Bar announced the appointment of Jon Vingo as Chief Development Officer to lead its restaurant development strategy. With over two decades of experience in multi-unit restaurant growth and operations, Vingo will oversee real estate, site selection, prototype design, and construction. This move supports Black Rock Coffee Bar’s goal…
Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company specializing in oral delivery of biologics and drugs via its proprietary RaniPill® technology, announced participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The management team will present via a fireside chat and one-on-one meetin…
Reid Alan McWilliams, the Executive Vice President of Global Human Resources at Sanmina Corp (NASDAQ: SANM), executed a sale of company common stock on May 8, 2026. The transaction involved 1,000 shares sold at a price of $248.60 per share, totaling a liquidation value of $248,600. This divestment occurs against a backdrop of significant stock pric…
Jeffrey Zerillo, who serves as the Senior Vice President of Operations at Prestige Consumer Healthcare Inc. (NASDAQ:PBH), has executed a sale of company common stock. The transaction, which took place on May 11, 2026, involved the disposal of 351 shares at a price point of $52.28 per share, resulting in total proceeds of $18,350. Following this div…
Symbotic (SYM) has the ingredients for meaningful revenue conversion over the next 12-18 months: a $22.3B backlog, improving GAAP profitability, and JV and acquisition catalysts. Technical momentum is weak and valuation is premium, but a structured trade with a $51 entry, $45 stop and $70 target balances upside vs execution risk.
Kyverna Therapeutics announced the initiation of a rolling Biologics License Application (BLA) submission to the FDA for its CAR T-cell therapy, mivocabtagene autoleucel (miv-cel), targeting stiff person syndrome (SPS). The company gained FDA alignment on the regulatory path following a positive pre-BLA meeting. Recent trial data demonstrated robus…
CSX Corporation's Board of Directors has approved a quarterly dividend of $0.14 per share, payable on June 15, 2026, to shareholders of record as of May 29, 2026. CSX is a major transportation company specializing in rail, intermodal, and rail-to-truck transload services across various sectors including energy, industrial, construction, agricultura…
Kura Oncology posted $5.8 million in net product revenue from KOMZIFTI in the first full quarter since commercialization, showing strong physician adoption and payer coverage. The company is advancing multiple clinical trials for ziftomenib in AML, with anticipated 2026 data readouts supporting its broad use. The robust cash position and collaborat…
Aura Biosciences, a clinical-stage biotech company specializing in precision therapies for solid tumors, announced that its senior management will participate in two major investor conferences in May 2026 to discuss the company's developments and outlook. Live webcasts will be available and archived on the company's investor relations website.
IZEA Worldwide reported a Q1 2026 revenue of $6.6 million, an 18% decrease year-over-year, reflecting their strategic shift away from low-margin SMB accounts toward higher-value enterprise clients. Despite the revenue decline and a net loss of $0.8 million, the company launched ZED, an AI-powered marketing platform, secured new major clients, and m…
Pacira BioSciences issued a letter to its stockholders ahead of the 2026 Annual Meeting, advocating for votes in favor of its three board nominees. The company emphasizes the nominees' extensive experience in healthcare and biopharmaceutical sectors aligned with Pacira's strategic goals, contrasted against the underqualified nominees proposed by ac…
Inhibikase Therapeutics announced the commencement of its pivotal Phase 3 IMPROVE-PAH clinical trial targeting Pulmonary Arterial Hypertension (PAH) with its lead candidate IKT-001. The company secured regulatory approvals across 16 countries including the US and EU, benefiting from the EMA's FAST-EU initiative to expedite trial sites activation. F…
Verrica Pharmaceuticals reported a 51.3% year-over-year increase in dispensed YCANTH applicator units and $5.0 million revenue in Q1 2026, highlighting growing adoption of their FDA-approved treatment for molluscum. The company advanced its global Phase 3 trial enrollment for YCANTH's new use in common warts and expanded commercial launch into Japa…
